Enlonstobart

Inquire / Price
  • Model Number:
    RL3220250101
  • Brand Name:
    恩舒幸
  • Origin:
    Original invention from China
  • Small Orders:
    Small batches also available
  • Tags:
Inquire Now Link

Poster
  • Details
  • Description
  • Packaging Size
    1bottle/Box
  • Strength
    100mg(10ml)
  • Compositon
    Enlonstobart
  • Treatment
    PD-L1 positive cervical cancer
  • Form
    Injection
  • Brand
    恩舒幸
  • Quantity Unit
    100mg(10ml)/Box
  • Manufacturer
    CSPC Pharmaceutical Group.,China

Enlonstobart, a recombinant, fully humanised immunoglobulin G4 monoclonal antibody targeted against programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.

  • Enlonstobart sold under the brand name 恩舒幸 (Enshuxing) ® in china. 

Enlonstobart received its first approval (a conditional marketing authorisation) in June 2024, in China, for use in patients with recurrent or metastatic programmed cell death ligand 1 (PD-L1)-positive cervical cancer who have failed previous platinum-containing chemotherapy. 


Link

Poster

Top